(Q37830361)

English

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

scientific article published on March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 August 2017

1 reference

Europe PubMed Central

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy (English)

1 reference

Europe PubMed Central

24 August 2017

1 reference

based on heuristic

inferred from title

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Eric Tartour

0 references

4

object named as

M Terme

1 reference

Europe PubMed Central

24 August 2017

6

object named as

J Taieb

1 reference

Europe PubMed Central

24 August 2017

author name string

H Pere

2

1 reference

Europe PubMed Central

24 August 2017

B Maillere

3

1 reference

Europe PubMed Central

24 August 2017

N Merillon

5

1 reference

Europe PubMed Central

24 August 2017

F Sandoval

7

1 reference

Europe PubMed Central

24 August 2017

F Quintin-Colonna

8

1 reference

Europe PubMed Central

24 August 2017

K Lacerda

9

1 reference

Europe PubMed Central

24 August 2017

A Karadimou

10

1 reference

Europe PubMed Central

24 August 2017

C Badoual

11

1 reference

Europe PubMed Central

24 August 2017

A Tedgui

12

1 reference

Europe PubMed Central

24 August 2017

W H Fridman

13

1 reference

Europe PubMed Central

24 August 2017

S Oudard

14

1 reference

Europe PubMed Central

24 August 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

24 August 2017

Cancer and Metastasis Reviews

1 reference

Europe PubMed Central

24 August 2017

30

1 reference

Europe PubMed Central

24 August 2017

1

1 reference

Europe PubMed Central

24 August 2017

83-95

1 reference

Europe PubMed Central

24 August 2017

https://scigraph.springernature.com/pub.10.1007/s10555-011-9281-4

0 references

Treatment options in renal cell carcinoma: past, present and future

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Bevacizumab: current updates in treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Tumor inflammatory angiogenesis and its chemoprevention

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Paradoxical roles of the immune system during cancer development

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

The role of myeloid cells in the promotion of tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Role of tumor-associated macrophages in tumor progression and invasion

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Pro-angiogenic cytokines and their role in tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

T(H)17 cells in tumour immunity and immunotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

IL-17 contributes to angiogenesis in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

The Soluble Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Inhibition of angiogenesis in vivo by interleukin 12.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

IL-12 regulates VEGF and MMPs in a murine breast cancer model

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Antiangiogenic and antitumor activities of IL-27.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Angiostatic activity of the antitumor cytokine interleukin-21.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Current status of interleukin-2 therapy in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Tuning microenvironments: induction of regulatory T cells by dendritic cells

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Tregs and rethinking cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

VEGFR2 is selectively expressed by FOXP3high CD4+ Treg.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

VEGF as a mediator of tumor-associated immunodeficiency

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Bv8 regulates myeloid-cell-dependent tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

STAT 3 as a target for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Role of Stat3 in suppressing anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

The STATs of cancer--new molecular targets come of age

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Costimulation, coinhibition and cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

A dialogue between the hypoxia-inducible factor and the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Clinical biomarkers of angiogenesis inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Serum soluble interleukin–2 receptor concentrations as an independent prognostic marker in head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Synergy between tumor immunotherapy and antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

The angiogenic growth factor and biomarker midkine is a tumor-shared antigen

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

BRAF, a target in melanoma: implications for solid tumor drug development

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2α but not HIF-1α

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9281-4

21 January 2018

Identifiers

10.1007/S10555-011-9281-4

1 reference

Europe PubMed Central

24 August 2017

1 reference

Europe PubMed Central

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37830361&oldid=2107050904"